Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$121.87
+2.2%
$114.04
$96.43
$153.84
$34.62B1.231.84 million shs1.04 million shs
Bruker Corporation stock logo
BRKR
Bruker
$42.54
+3.1%
$38.98
$34.10
$72.94
$6.45B1.181.72 million shs1.24 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$157.94
+2.6%
$141.48
$91.86
$254.15
$7.76B1.491.03 million shs376,629 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$52.86
+2.6%
$49.96
$46.01
$83.62
$8.29B1.391.46 million shs1.07 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
-1.61%+0.97%+2.85%+20.45%-5.67%
Bruker Corporation stock logo
BRKR
Bruker
-2.71%+0.17%+7.75%+13.50%-33.06%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-2.03%+1.51%+6.36%+24.67%-22.90%
Bio-Techne Corp stock logo
TECH
Bio-Techne
-3.02%+0.16%+5.83%+5.57%-27.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
4.7313 of 5 stars
3.34.02.53.63.40.81.3
Bruker Corporation stock logo
BRKR
Bruker
4.7697 of 5 stars
3.21.01.73.82.45.01.9
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.0706 of 5 stars
2.12.00.04.72.42.51.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.9716 of 5 stars
4.25.01.74.23.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
2.54
Moderate Buy$139.7714.69% Upside
Bruker Corporation stock logo
BRKR
Bruker
2.40
Hold$52.8924.33% Upside
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.19
Hold$171.858.80% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0036.21% Upside

Current Analyst Ratings Breakdown

Latest TECH, BRKR, A, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$125.00 ➝ $130.00
6/26/2025
Bruker Corporation stock logo
BRKR
Bruker
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$61.00 ➝ $50.00
6/24/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $125.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$135.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/29/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$150.00 ➝ $130.00
5/29/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$160.00 ➝ $155.00
5/29/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$150.00
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/22/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$159.00 ➝ $140.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$6.51B5.32$6.28 per share19.42$20.53 per share5.94
Bruker Corporation stock logo
BRKR
Bruker
$3.37B1.91$3.60 per share11.82$11.85 per share3.59
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.92$21.81 per share7.24$67.80 per share2.33
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.15$2.30 per share22.97$13.13 per share4.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.29B$4.0530.0920.043.6817.59%25.92%13.24%8/20/2025 (Estimated)
Bruker Corporation stock logo
BRKR
Bruker
$113.10M$0.5281.8113.502.852.31%19.47%5.95%8/5/2025 (Estimated)
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.365.32-0.66%15.19%6.93%8/6/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8264.4626.832.5310.89%13.17%10.17%8/6/2025 (Estimated)

Latest TECH, BRKR, A, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Bruker Corporation stock logo
BRKR
Bruker
$0.43N/AN/AN/A$811.17 millionN/A
5/28/2025Q2 2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.26$1.31+$0.05$0.75$1.63 billion$1.67 billion
5/7/2025Q1 2025
Bruker Corporation stock logo
BRKR
Bruker
$0.46$0.47+$0.01$0.11$763.83 million$801.40 million
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$0.990.81%N/A24.44%9 Years
Bruker Corporation stock logo
BRKR
Bruker
$0.200.47%N/A38.46%N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.61%N/A39.02%N/A

Latest TECH, BRKR, A, and CRL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2025
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
quarterly$0.24800.9%7/1/20257/1/20257/23/2025
5/12/2025
Bruker Corporation stock logo
BRKR
Bruker
quarterly$0.050.5%6/16/20256/16/20256/27/2025
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.55
2.09
1.60
Bruker Corporation stock logo
BRKR
Bruker
1.13
1.57
0.74
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Bruker Corporation stock logo
BRKR
Bruker
79.52%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Bruker Corporation stock logo
BRKR
Bruker
27.30%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
17,900284.07 millionN/AOptionable
Bruker Corporation stock logo
BRKR
Bruker
11,396151.53 million110.16 millionOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Is Bio-Techne Stock Underperforming the Nasdaq?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agilent Technologies stock logo

Agilent Technologies NYSE:A

$121.87 +2.62 (+2.20%)
As of 03:04 PM Eastern

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Bruker stock logo

Bruker NASDAQ:BRKR

$42.54 +1.27 (+3.08%)
As of 03:04 PM Eastern

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$157.94 +4.04 (+2.63%)
As of 03:04 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$52.86 +1.32 (+2.56%)
As of 02:57 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.